We are live on
!
Find out more
AC
Armistice Capital Portfolio holdings
AUM
$5.62B
1-Year Est. Return
36.06%
This Fund
S&P 500
This Quarter
Est. Return
+0.48%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$263M
AUM Growth
+$7.9M
(+3.1%)
Cap. Flow
+$8.82M
Cap. Flow
% of AUM
3.36%
Top 10 Holdings %
Top 10 Hldgs %
45.52%
Holding
58
New
24
Increased
7
Reduced
13
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARLZ
Aralez Pharmaceuticals Inc.
ARLZ
|
+$10.1M |
| 2 |
SGI
Somnigroup International
SGI
|
+$8.5M |
| 3 |
Tenet Healthcare
THC
|
+$6.74M |
| 4 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$6.47M |
| 5 |
Enanta Pharmaceuticals
ENTA
|
+$6.28M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
XNPT
XENOPORT, INC.
XNPT
|
+$12.8M |
| 2 |
AVTA
Avantax, Inc. Common Stock
AVTA
|
+$11.1M |
| 3 |
TVTY
Tivity Health, Inc. Common Stock
TVTY
|
+$8.48M |
| 4 |
Vanda Pharmaceuticals
VNDA
|
+$7.75M |
| 5 |
Theravance Biopharma
TBPH
|
+$7.52M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 38.23% |
| 2 | Consumer Discretionary | 24.75% |
| 3 | Consumer Staples | 7.97% |
| 4 | Financials | 1.97% |
| 5 | Communication Services | 1.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BLUE
26
DELISTED
bluebird bio
BLUE
| $4.16M | 1.58% |
+7,411
| New | +$4.2M |
|
|
NILE
27
DELISTED
Blue Nile, Inc.
NILE
| $4.05M | 1.54% |
+148,000
| New | +$3.85M |
|
28
Papa John's
PZZA
$1.08B
| $3.94M | 1.5% |
+58,000
| New | +$3.54M |
|
|
DFRG
29
DELISTED
Del Frisco's Restaurant Group, Inc. Common Stock
DFRG
| $3.9M | 1.48% |
+272,000
| New | +$4.24M |
|
|
HABT
30
DELISTED
The Habit Restaurants, Inc. - Class A
HABT
| $3.87M | 1.47% |
+236,000
| New | +$4.09M |
|
|
AVDL
31
DELISTED
Avadel Pharmaceuticals
AVDL
| $3.74M | 1.42% |
+348,003
| New | +$3.71M |
|
|
LEAF
32
DELISTED
Leaf Group Ltd.
LEAF
| $3.72M | 1.42% |
720,000
-376,000
| -34% | -$2.06M |
|
33
RH
RH
$3.56B
| $3.67M | 1.4% |
+128,000
| New | +$4.58M |
|
34
Red Rock Resorts
RRR
$3.79B
| $3.47M | 1.32% |
+158,000
| New | +$3.22M |
|
35
Bath & Body Works
BBWI
$4.21B
| $3.36M | 1.28% |
+61,850
| New | +$3.62M |
|
36
Tenax Therapeutics
TENX
$420M
| $2.84M | 1.08% |
35
-2
| -5% | -$167K |
|
|
TTPH
37
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
| $2.07M | 0.79% |
+24,104
| New | +$2.21M |
|
|
QLTI
38
DELISTED
QLT Inc
QLTI
| $1.56M | 0.59% |
+1,095,455
| New | +$1.69M |
|
39
SCYNEXIS
SCYX
$42.4M
| $1.51M | 0.58% |
+8,725
| New | +$2.47M |
|
40
Arbutus Biopharma
ABUS
$901M
| $1.42M | 0.54% |
+408,000
| New | +$1.73M |
|
41
Lipocine
LPCN
$18.4M
| $1.22M | 0.46% |
+23,529
| New | +$3.64M |
|
|
AEGR
42
DELISTED
Aegerion Pharmaceuticals
AEGR
| $1.19M | 0.45% |
800,000
-698,000
| -47% | -$1.6M |
|
|
XYLO
43
DELISTED
Xylo Technologies
XYLO
| $625K | 0.24% |
387
| – | – |
|
|
ODP
44
CALL
DELISTED
ODP
ODP
| $463K | 0.18% |
+13,990
| New | +$683K |
|
45
Madrigal Pharmaceuticals
MDGL
$12.8B
| $156K | 0.06% |
+17,143
| New | +$206K |
|
46
Chefs' Warehouse
CHEF
$3.96B
| – | – |
-176,000
| Closed | -$3.57M |
|
47
Kodak
KODK
$750M
| – | – |
-78,000
| Closed | -$846K |
|
48
Dave & Buster's
PLAY
$354M
| – | – |
-98,000
| Closed | -$3.8M |
|
|
49
Theravance Biopharma
TBPH
$877M
| – | – |
-400,000
| Closed | -$7.52M |
|
50
United Parks & Resorts
PRKS
$2.13B
| – | – |
-56,000
| Closed | -$1.18M |
|
Similar funds
CRC
RMDI
F
DWM
DCP
EW
AIM
O
Armistice Capital's Q2 2016 Portfolio in Review
As of Q2 2016, Armistice Capital held 58 positions worth $263M, up 3.1% from $255M the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Armistice Capital deployed $8.82M of net new capital in Q2 2016, opening 24 new positions and adding to 7 existing holdings. Its largest new stake was Aralez Pharmaceuticals Inc.: 2,664,000 shares worth $8.79M.
By sector, the portfolio is most concentrated in Healthcare at 38% of assets, up from 38% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.
On the sell side, the largest reduction was Avantax, Inc. Common Stock, an estimated $11.1M trimmed.
- Armistice Capital's largest Q2 2016 buy was Aralez Pharmaceuticals Inc.: 2,664,000 shares worth $8.79M.
- Armistice Capital added most to Tailored Brands, Inc. in Q2 2016, an estimated $4.26M increase.
- Armistice Capital's biggest Q2 2016 reduction was Avantax, Inc. Common Stock, cutting an estimated $11.1M.
- Armistice Capital fully exited XENOPORT, INC. in Q2 2016, selling an estimated $12.8M.
- Armistice Capital's ten largest holdings make up 46% of its $263M portfolio in Q2 2016.
- Armistice Capital opened 24 new positions and closed 12 in Q2 2016.
- Armistice Capital's portfolio value rose 3.1% quarter-over-quarter to $263M.
Based on Armistice Capital's 13F filing for Q2 2016, filed 15 Aug 2016.